NDAORALSUSPENSION
Approved
Jan 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFATRIM (sulfamethoxazole and trimethoprim) by Inpharmus is cytochrome p450 2c9 inhibitors [moa]. First approved in 1983.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULFATRIM is an oral suspension containing sulfamethoxazole and trimethoprim, a fixed-dose combination antibiotic indicated for bacterial infections. It works by inhibiting cytochrome P450 2C9 and disrupting bacterial folate synthesis through dual sulfonamide mechanism. This classic combination agent has been a cornerstone of infectious disease treatment since approval in 1983.
LOE Approaching
As LOE approaches with moderate competitive pressure (30/100), the brand team will shift from growth initiatives to lifecycle extension and managed decline strategies.
Mechanism of Action
Cytochrome P450 2C9 Inhibitors
Pharmacologic Class:
Sulfonamide Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SULFATRIM offers exposure to lifecycle management in a mature antibiotic franchise facing LOE; career growth favors strategic roles in pricing, payer negotiations, and competitive repositioning. Limited headcount and job openings (0 linked roles) reflect the product's stable, legacy status and declining investment.
Brand Manager
Worked on SULFATRIM at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.